All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
20 results for "Cancer" and "Head and Neck Cancers" and "Multiple Myeloma"
AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at Least 2 lines of Systemic Therapy.
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease.
Protocol No
SYNDAX-SNDX-6352-0504-CGVHD
Sub Category
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Protocol No
GENMAB-GCT3014-01
Sub Category
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within One Year of Initial Treatment (KarMMa-2)
An Efficacy and Safety Study of bb2121 in Subjects with rrMM and in Subjects with High-risk MM
Protocol No
CELGENE-BB2121-MM-002-KARMMA2
Sub Category
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Protocol No
KANGPU-KPG-818-HEM-101
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings ...
Protocol No
JANSSEN-64407564MMY1002
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study Of AEVI-007 In Subjects With Relapsed Or Refractory Multiple Myeloma
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Protocol No
AEVI-007-MM-101
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy & Safety of Belantamab Mafodotin in Combination with Pomalidomide & Dex (B-Pd) versus Pomalidomide plus Bortezomib & Dex (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Protocol No
GSK-207499-DREAMM-08
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Protocol No
CAELUM-CAEL101-301
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIa AL Amyloid
Protocol No
CAELUM-CAEL101-302
Sub Category
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Protocol No
IIT-DHAKAL-VICD-MM
Sub Category
A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
A Study to Evaluate the Safety of bb2121 in Subjects with High Risk NDMM (KarMMa4)
Protocol No
CELGENE-BB2121-MM-004-KARMMA4
Sub Category
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients: inflammatory mechanisms
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients
Protocol No
IIT-KNIGHT-SLEEPHCT
Sub Category
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for RR MM
Protocol No
RAPA-201-RRMM
Sub Category
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortexomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma
NJ-68284528 a CAR-T directied against BCMA vs PVd or DPd in pt with rr MM (CARTITUDE-4)
Protocol No
JANSSEN-JNJ-68284528-MMY3002
Sub Category
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Belantamab mafodotin vs pom/dex in RRMM
Protocol No
GSK-207495-DREAMM-03
Sub Category
A Phase II, Open-Label, Study of Propylene Glycol-Free Melphalan HCL (EVOMELA®) in Combination with Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
EVOMELA In Combination With Fludarabine and TBI based reduced intensity conditioning for Haplo BMT
Protocol No
IIT-HAMADANI-FLU-MEL-TBI
Sub Category
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide OR Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with MM Using MRD To Direct Therapy Duration (DRAMMATIC STUDY)
S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Protocol No
SWOG-S1803-CTN-1706-DRAMMATIC
Sub Category
Alliance-A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with CLL
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia
Protocol No
ALLIANCE-A041702-CLL
Sub Category
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639